Login to Your Account

Plexcera Tackling Rare, Oft-Misdiagnosed Farber Disease

By Jennifer Boggs
Managing Editor

Friday, September 13, 2013
Pitching a rare disease program to prospective partners and investors these days sounds like it should be a fairly easy task. Biotech and pharma firms have more than 500 programs in the rare disease pipeline and orphan indications are an increasingly hot property for the industry. (See BioWorld Insight, April 29, 2013.)

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription